Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.53 |
| ▸ | ITGAV | P06756 | 16/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | MMP12 | P39900 | 3/20 | 0.40 |
| ▸ | MMP14 | P50281 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7404829 | 0.96 | ITGB3 (0.52) | ITGB3ITGAVITGA2B | |
| SCHEMBL7982469 | 0.92 | ITGB3 (0.56) | ITGB3ITGAVITGA2B | |
| SCHEMBL7399085 | 0.90 | ITGB3 (0.56) | ITGB3ITGAVITGA2B | |
| SCHEMBL7399485 | 0.89 | ITGB3 (0.56) | ITGB3ITGAVITGA2B | |
| SCHEMBL7404043 | 0.89 | ITGB3 (0.52) | ITGB3ITGAVITGA2BMMP2MMP9 | |
| SCHEMBL7399265 | 0.88 | ITGB3 (0.54) | ITGB3ITGAVITGA2B | |
| SCHEMBL7403933 | 0.87 | ITGB3 (0.70) | ITGB3ITGAVITGA2B | |
| SCHEMBL7404741 | 0.87 | ITGB3 (0.55) | ITGB3ITGAVITGA2B | |
| SCHEMBL7400646 | 0.86 | ITGB3 (0.53) | ITGB3ITGAVITGA2BMMP2MMP9 | |
| SCHEMBL7406689 | 0.85 | ITGB3 (0.50) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |